Dec 19 |
PaxMedica CEO Howard Weisman Sheds Light on Achievements for ASD Therapy Pipeline
|
Dec 12 |
PaxMedica Inc. Covered in H.C. Wainwright & Co. Research Report
|
Dec 8 |
PaxMedica CEO Featured in Just-Released Fireside Chat Video
|
Dec 7 |
PaxMedica Closes Public Offering of Approximately $7M, Continues Pursuing ASD Pipeline
|
Dec 6 |
PaxMedica Releases Fireside Chat Video with CEO Howard Weisman
|
Dec 1 |
PaxMedica Closes on Public Offering Reaching Estimated $7M
|
Nov 22 |
PaxMedica Announces Closing of $7.0 Million Public Offering
|
Nov 22 |
PaxMedica Announces Pricing of $7M Public Offering
|
Nov 21 |
PaxMedica News of FDA Type-B Meeting Shared in Audio Broadcast
|
Nov 20 |
PaxMedica prices 5.38M shares at $1.30 in public offering
|